Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

161. Effectiveness of e-health based self-management to improve cancer-related fatigue, self-efficacy and quality of life in cancer patients: systematic review and meta-analysis (Abstract)

Effectiveness of e-health based self-management to improve cancer-related fatigue, self-efficacy and quality of life in cancer patients: systematic review and meta-analysis To integrate the overall effect of e-health based self-management on cancer-related fatigue (CRF), self-efficacy, and quality of life (QOL) among adult cancer patients.A systematic review and meta-analysis of randomized controlled trials.We researched PubMed, Cumulative Index Nursing and Allied Health Literature, Cochrane

2019 EvidenceUpdates

162. Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission

Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast (...) Cancer Order Download: Key message Background Breast cancer can be treated with chemotherapy, hormone therapy and radiation, or a combination of these to prevent the spread of cancer cells, after surgical removal of the tumor. When assessing whether a patient should be offered chemotherapy, information about prognosis is important. Patients at high risk of recurrence should be offered chemotherapy, while patients at low risk are not very likely to gain from such treatment, in which case side effects

2019 Norwegian Institute of Public Health

163. Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance

Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance Guideline Endorsement 7-13-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National (...) Institute for Health and Care Excellence Guidance M. Taremi, E.T. Vella, S. Cheng, P.M. Ellis, R. Goffin, A. Louie, R. MacRae, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: November 11, 2019 This document describes the CCO-Lung Cancer Disease Site Group endorsement of the recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available

2019 Cancer Care Ontario

164. Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial) (Abstract)

Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial) A survival benefit of extensive intraoperative peritoneal lavage (EIPL) has been reported in patients with gastric cancer with positive peritoneal cytology. The hypothesis of this study was that EIPL may reduce peritoneal recurrence in patients with advanced gastric cancer who undergo surgery with curative intent.This was an open-label, multi (...) -institutional, randomized, phase 3 trial to assess the effects of EIPL versus standard treatment after curative gastrectomy for resectable gastric cancer of T3 status or above. The primary endpoint was disease-free survival (DFS); secondary endpoints were overall survival, peritoneal recurrence-free survival and incidence of adverse events.Between July 2011 and January 2014, 314 patients were enrolled from 15 institutions and 295 patients were analysed (145 and 150 in the EIPL and no-EIPL groups

2019 EvidenceUpdates

165. Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study) (Abstract)

Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study) Upper gastrointestinal malignancies have a poor prognosis. There is no consensus on how patients should be followed after surgery. The authors hypothesized that a structured follow-up programme including endoscopic ultrasonography (EUS) and [18 F]fluorodeoxyglucose (FDG) PET/CT would detect cancer recurrences, leading (...) chemotherapy (P = 0·028). Although survival after detection of recurrence in asymptomatic patients was significantly longer than that for symptomatic patients (P < 0·001), overall survival from date of surgery in the two treatment groups was comparable.Follow-up after surgery for upper gastrointestinal cancer with EUS and PET/CT leads to detection of more asymptomatic cancer recurrences and patients referred for treatment without prolonging overall survival. Registration number: NCT02209415 ( http

2019 EvidenceUpdates

166. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial (Abstract)

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial Platinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both significantly improve efficacy versus standard therapy, primarily in terms of progression-free survival, and offer (...) the potential for chemotherapy-free treatment. AVANOVA2 compared niraparib and bevacizumab versus niraparib alone as definitive treatment for platinum-sensitive recurrent ovarian cancer.This open-label, randomised, phase 2, superiority trial in 15 university hospitals in Denmark, Sweden, Finland, Norway, and the USA enrolled women aged 18 years or older with measurable or evaluable high-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer. Patients had to have an Eastern Cooperative

2019 EvidenceUpdates

167. Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial (Abstract)

Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial The aim of this study was to report the 3-year survival results of the GRECCAR-6 trial.Current data on the effect of an extended interval between radiochemotherapy (RCT) and resection for rectal cancer on the rate of complete pathological response (pCR = ypT0N0) is controversial. Furthermore, its (...) ) recurrences were also not influenced by the waiting period. DFS was independently influenced by 3 factors: circumferential radial margin (CRM) ≤1 mm [hazard ratio (HR) = 2.03; 95% confidence interval (CI), 1.17-3.51], ypT3-T4 (HR = 2.69; 95% CI, 1.19-6.08) and positive lymph nodes (HR = 3.62; 95% CI, 1.89-6.91).Extending the waiting period by 4 weeks following RCT has no influence on the oncological outcomes of T3/T4 rectal cancers.

2019 EvidenceUpdates

168. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis Full Text available with Trip Pro

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis Although international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line (...) trials investigating chemotherapy with or without targeted therapies and hormone therapies with or without targeted therapies as first-line or second-line treatments, or both, in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, published between Jan 1, 2000, and Dec 31, 2017. Additional recently published randomised controlled trials relevant to the topic were also subsequently added. No language restrictions were adopted for our search. A Bayesian network

2019 EvidenceUpdates

169. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study (Abstract)

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive (...) metastatic breast cancer in an open-label, multicenter, randomized phase II study.Chinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14). The primary end point was investigator-assessed overall response rate per Response Evaluation

2019 EvidenceUpdates

170. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial Full Text available with Trip Pro

Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial Laparoscopic distal gastrectomy and neoadjuvant chemotherapy are increasingly used to treat locally advanced gastric cancer. However, the safety and efficacy of the laparoscopic procedure after neoadjuvant chemotherapy remain unclear.To evaluate the short-term outcomes of patients with locally advanced gastric cancer who received either laparoscopic (...) distal gastrectomy or open distal gastrectomy.Between April 23, 2015, and November 16, 2017, a phase 2, open-label, noninferiority randomized clinical trial was conducted at the Gastrointestinal Cancer Center of Peking University Cancer Hospital and Institute in Beijing, China. Patients (n = 96) between 18 and 80 years of age with locally advanced gastric cancer (cT2-4aN+M0) who were receiving neoadjuvant chemotherapy were enrolled and randomized. An as-treated population and a modified intention

2019 EvidenceUpdates

171. Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis Full Text available with Trip Pro

Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis Evaluate effectiveness, harms and burdens of faecal blood testing, sigmoidoscopy and colonoscopy screening for colorectal cancer over 15 years.We performed an update of a Cochrane systematic review, and performed network meta-analysis comparing randomised trials evaluating colorectal cancer screening with guaiac faecal occult blood test (gFOBT) (annual, biennial), faecal (...) immunochemical test (FIT) (annual, biennial), sigmoidoscopy (once-only) or colonoscopy (once-only) in a healthy population, aged 50-79 years. We conducted subgroup analysis on sex. Follow-up >5 years was required for analysis of colorectal cancer incidence and mortality.12 randomised trials proved eligible. Compared with no-screening, we found high certainty evidence for sigmoidoscopy screening slightly reducing colorectal cancer incidence (relative risk (RR) 0.76; 95% confidence interval (CI 0.70 to 0.83

2019 EvidenceUpdates

172. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer (Abstract)

Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer Current guidelines recommend that women delay pregnancy for 6 to 12 months after the receipt of radioactive iodine treatment (RAIT) following thyroidectomy for differentiated thyroid carcinoma. Although concerns exist regarding the risks associated with pregnancy after RAIT, no large-scale study, to date, has investigated the association between RAIT and pregnancy (...) outcomes.To investigate whether RAIT was associated with increases in adverse pregnancy outcomes among South Korean women who received RAIT after thyroidectomy for thyroid cancer and to evaluate the appropriate interval between RAIT and conception.This population-based cohort study used the Health Insurance Review and Assessment database of South Korea to identify a total of 111 459 women of childbearing age (20-49 years) who underwent thyroidectomy for the treatment of differentiated thyroid carcinoma

2019 EvidenceUpdates

173. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial (Abstract)

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume (...) ovarian function after chemotherapy.We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years

2019 EvidenceUpdates

174. Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis The safety profile of interleukin (IL) inhibitors is not well established.To assess the risk of serious infections, opportunistic infections, and cancer in patients with rheumatologic diseases treated with IL inhibitors.Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations; Ovid MEDLINE Daily; Ovid Embase; Ovid Cochrane Central (...) and certainty in the evidence. Fixed-effects meta-analysis was conducted to pool odds ratios (ORs) for serious infections, opportunistic infections, and cancers for IL inhibitors vs placebo.The outcomes of interest were the number of serious infections, opportunistic infections, and cancers in individuals receiving IL inhibitor therapies compared with placebo.In this meta-analysis, 74 studies comprising 29 214 patients (24 236 patients for serious infections, 9998 for opportunistic infections, and 21 065

2019 EvidenceUpdates

175. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions WHO guidelines for the use of thermal ablation for cervical pre-cancer lesionsWHO guidelines for the use of thermal ablation for cervical pre-cancer lesions WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions ISBN 978-92-4-155059-8 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC (...) Property Organization. Suggested citation. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party

2019 World Health Organisation Guidelines

176. 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)

18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages) NHS England » 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages) Search Search Menu 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy (...) treatment planning for oesophageal cancer (all ages) Document first published: 12 April 2019 Page updated: 12 April 2019 Topic: Publication type: , NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current

2019 NHS England

177. Proton Beam Therapy for Head and Neck Cancer in Adults

Proton Beam Therapy for Head and Neck Cancer in Adults NHS England » Proton Beam Therapy for Head and Neck Cancer in Adults Search Search Menu Proton Beam Therapy for Head and Neck Cancer in Adults Document first published: 23 July 2019 Page updated: 23 July 2019 Topic: Publication type: , NHS England has reviewed the evidence to treat head and neck cancer in adults with proton beam therapy and have concluded that there is not enough evidence to make the treatment available through routine

2019 NHS England

178. Proton Beam Therapy for Oesophageal Cancer in Adults

Proton Beam Therapy for Oesophageal Cancer in Adults NHS England » Proton Beam Therapy for Oesophageal Cancer in Adults Search Search Menu Proton Beam Therapy for Oesophageal Cancer in Adults Document first published: 23 July 2019 Page updated: 23 July 2019 Topic: Publication type: , NHS England has reviewed the evidence to treat oesophageal cancer with proton beam therapy (PBT) in adults and have concluded that there is not enough evidence to make the treatment available through routine

2019 NHS England

179. Influence of delay on breast cancer surgery outcome

Influence of delay on breast cancer surgery outcome Influence of delay on breast cancer surgery outcome We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Influence of delay on breast cancer surgery outcome Share: Reading time approx. 5 minutes In Sweden as well as worldwide, breast cancer is the most common cancer diagnosis in women, and surgery (...) is the primary treatment for curative care. As the time between diagnosis and surgery can vary substantially, it is essential to know if wait time for operative procedures may influence surgery outcomes. Question What systematic reviews are there on surgical wait time and medical outcomes in breast cancer patients? Identified literature No relevant systematic reviews with low/medium risk of bias were found. SBU Enquiry Service consists of systematic literature searches to highlight studies that can address

2019 Swedish Council on Technology Assessement

180. Hyperthermia treatment in cancer

Hyperthermia treatment in cancer Hyperthermia treatment in cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Hyperthermia treatment in cancer Share: Reading time approx. 10 minutes Heating tumours can make them more susceptible to treatment or have a direct active effect by killing of tumour tissue. The proposed mechanism for hyperthermia (...) treatment is that the tumour is more susceptible to heat than the surrounding healthy tissue and that hyperthermia enhances the cell damaging effect of chemotherapy and radiation. It is however unclear if hyperthermia treatment has an effect when it is not combined with chemotherapy or radiation. Questions What scientific studies are there on the effect of hyperthermia treatment on cancer, when not combined with chemotherapy or radiation? What systematic reviews are there on the effect of hyperthermia

2019 Swedish Council on Technology Assessement